Merck KGaA (OTCMKTS:MKKGY - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $0.48 per share and revenue of $5.34 billion for the quarter.
Merck KGaA (OTCMKTS:MKKGY - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.50 by $0.09. The business had revenue of $5.89 billion for the quarter, compared to analysts' expectations of $5.32 billion. Merck KGaA had a net margin of 13.23% and a return on equity of 9.61%. On average, analysts expect Merck KGaA to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Merck KGaA Price Performance
Shares of OTCMKTS MKKGY traded down $0.06 during midday trading on Friday, reaching $24.96. 211,878 shares of the company traded hands, compared to its average volume of 127,024. The firm has a market cap of $16.13 billion, a PE ratio of 11.82, a PEG ratio of 1.98 and a beta of 0.91. The stock's 50-day simple moving average is $26.09 and its 200-day simple moving average is $27.41. Merck KGaA has a 12 month low of $24.32 and a 12 month high of $39.17. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.83 and a current ratio of 1.31.
Merck KGaA Company Profile
(
Get Free Report)
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Read More
Before you consider Merck KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.
While Merck KGaA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access